AI
ByCan AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth Beyond 2026?
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Will Merck’s $9.2 Billion Acquisition of Cidara Therapeutics Reshape the Future of Long-Acting Influenza Prevention?
Rahway, NJ & San Diego, CA | January 2026 Merck & Co., Inc. has confirmed that its approximately…
Can Insilico Medicine’s Hong Kong IPO Signal a Turning Point for AI-Driven Drug Discovery in Global Capital Markets?
Hong Kong | January 4, 2026 Insilico Medicine, a China-based, AI-driven drug discovery company backed by Qiming Venture…
Is AI Now Shaping the Future of Biopharma R&D — and Who’s Leading the Transformation?
Executive Summary A recent Endpoints Signal Pulse Report reveals that half of biopharma professionals now consider themselves heavy…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
Can Insilico Medicine and China Medical System Accelerate AI-Discovered Drugs from Algorithm to Clinic?
Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China Medical System Holdings…
